Balchem Corporation (BCPC) News
Filter BCPC News Items
BCPC News Results
|Loading, please wait...|
BCPC News Highlights
- BCPC's 30 day story count now stands at 5.
- Over the past 21 days, the trend for BCPC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BCPC are MSM, RAM and SKIN.
Latest BCPC News From Around the Web
Below are the latest news stories about BALCHEM CORP that investors may wish to consider to help them evaluate BCPC as an investment opportunity.
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, September 21-22, 2022.
Blachem (BCPC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Balchem (BCPC - Research Report), with a price target of $164.00. The company's shares closed yesterday at $131.82.According to TipRanks, Selvaraju is an analyst with an average return of -31.0% and a 19.54% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Enlivex Therapeutics, and Brainsway.Balchem has an analyst consensus of Moderate Buy, with a price target consensus of $164.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $173.80 and a one-year low of $110.15. Currently, Balchem has an average volume of 110.2K.
NEW HAMPTON, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredients company focused on Nutrition and Health, today announced the acquisition of Cardinal Associates Inc., operating as “Bergstrom Nutrition,” a leading science-based manufacturer of methylsulfonylmethane (MSM), based in Vancouver, Washington. MSM is a widely used nutritional ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin a
BCPC, KEYS and AHT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 24, 2022.
In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Balchem (BCPC - Research Report), with a price target of $164.00. The company's shares closed last Friday at $138.00.According to TipRanks, Selvaraju is an analyst with an average return of -31.8% and a 20.60% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Aquestive Therapeutics, and Aeterna Zentaris.Balchem has an analyst consensus of Hold.See today’s best-performing stocks on TipRanks >>Based on Balchem's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $236.69 million and a net profit of $29.78 million.
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Thank you for joining our conference call this morning to discuss the results of Balchem Corporation for the quarter ending June 30, 2022. My name is Martin Bengtsson, chief financial officer; and hosting this call with me is Ted Harris, our chairman, CEO, and president. Following the advice of our counsel, auditors, and the SEC, at this time, I would like to read our forward-looking statement.
Balchem Corporation Reports Second Quarter Sales of $236.7 Million, Net Earnings of $29.8 Million, GAAP EPS of $0.92, and Adjusted EPS of $1.07
NEW HAMPTON, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today second quarter net earnings of $29.8 million for 2022, compared to net earnings of $22.7 million for the second quarter 2021, adjusted net earnings(a) of $34.4 million, compared to $30.4 million in the prior year quarter, and adjusted EBITDA(a) of $56.5 million, compared to $50.1 million in the prior year quarter. Second Quarter 2022 Financial Highlights: Record net sales were $236.7 million, a